Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we report on how lawsuits linked to Covid-19 are gaining prominence under the Trump administration. We also await Novo results on GLP-1 effects on Alzheimer’s, and more.
The need-to-know this morning
- Alkermes increased its takeout offer for Avadel Pharmaceuticals to $22.50 per share, topping a competing bid from Lundbeck.
- Agios Pharmaceuticals reported mixed results from a Phase 3 study in sickle cell disease that will likely dim hopes of securing a U.S. approval for its drug.
Novo nears release of high-stakes Alzheimer’s data for semaglutide
Novo Nordisk is set to soon unveil pivotal Phase 3 data on whether semaglutide — the blockbuster GLP-1 drug behind Ozempic and Wegovy — can slow Alzheimer’s progression. Expectations are muted, STAT’s Elaine Chen writes, but success could reshape both the company’s trajectory and the field.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply